Imugene Ltd has released a press release.
Annual Report and Appendix 4E
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Imugene
- First cohort 3 patient dosed in clinical trial of checkvacc
- Imugene Presents New PD1-Vaxx Data at the 2022 WCLC
- Final HER-Vaxx Phase 2 Trial Overall Survival Results
- Imugene doses first patient in vaxinia phase 1 trial
- IMU RECEIVES ETHICS APPROVAL TO START HER-VAXX NextHERIZON
Later from Imugene
- Imugene Dose Escalates in Phase I Clinical Trial of VAXINIA
- Imugene doses first patient in nextHERIZON Phase 2 trial
- Imugene announces a$80 million institutional placement
- Prospectus for the issue of institutional placement options
- OGTR grants VAXINIA DIR licence allowing trial expansion
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene